Peptides for Healing After Injury 2026: Sports, Surgery, Soft Tissue & Bone

Injury recovery is among the most compelling applications of therapeutic peptides, and arguably the area with the strongest and most consistent evidence across preclinical models. Whether you are dealing with a torn tendon, post-surgical recovery, stress fracture, or lingering soft tissue injury, several peptides have demonstrated the ability to meaningfully accelerate healing through distinct mechanisms.

This guide covers the most evidence-supported healing peptides, what they are best suited for, how they work, and practical protocol considerations.

Why Peptides Accelerate Healing

The body's natural healing process involves orchestrated phases: hemostasis, inflammation, proliferation, and remodeling. In many injuries—particularly chronic injuries, high-grade acute injuries, or post-surgical recovery in older adults—one or more phases is impaired. Healing peptides work by enhancing the biological signaling that drives these phases forward.

Key mechanisms include:

• Upregulation of growth factor expression (VEGF, FGF, TGF-β)
• Enhanced angiogenesis (new blood vessel formation into injured tissue)
• Promotion of fibroblast and tenocyte proliferation
• Modulation of the inflammatory response to prevent chronic inflammation without blocking necessary acute inflammation
• Improved extracellular matrix remodeling

BPC-157: The Foundational Healing Peptide

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a naturally occurring protein in human gastric juice. It has the most extensive preclinical evidence of any healing peptide, with over 80 published studies in animal models demonstrating accelerated healing of:

• Tendons (including Achilles tendon transection studies)
• Ligaments (ACL and MCL in animal models)
• Muscle tissue after crush or laceration injury
• Bone fractures
• Gastrointestinal tissue (esophagus, stomach, intestine, colon)
• Peripheral nerves
• Skin wounds

BPC-157 appears to work primarily by upregulating VEGF (vascular endothelial growth factor), promoting angiogenesis into avascular or poorly vascularized tissues like tendons. It also activates the nitric oxide system and modulates both dopaminergic and serotonergic neurotransmitter systems—which is relevant to its pain-modulatory effects.

Administration for injury:

• Systemic subcutaneous injection (200–500 mcg daily) for healing throughout the body
• Intralesional or peri-lesional injection (injecting directly into or near the injured tissue at 250–500 mcg) for localized injuries where maximum local effect is desired

Typical protocol duration: 4 to 8 weeks for acute injuries; 8 to 16 weeks for chronic injuries or post-surgical recovery.

BPC-157 has no documented serious side effects in animal models, even at very high doses, and anecdotal clinical safety data in humans is overwhelmingly positive. Human controlled trials are limited but ongoing. For a comprehensive review, see our BPC-157 guide.

TB-500 (Thymosin Beta-4): Systemic Repair and Inflammation Control

TB-500 is a synthetic version of the naturally occurring peptide thymosin beta-4, which plays a fundamental role in actin polymerization, cell migration, and tissue repair. Every cell in the body contains thymosin beta-4, and it is released in high concentrations at sites of injury.

TB-500's healing mechanisms complement BPC-157's:

• Promotes cell migration by sequestering G-actin
• Reduces inflammation by downregulating pro-inflammatory cytokines
• Stimulates new blood vessel formation
• Promotes satellite cell activation in muscle

TB-500 is particularly valued for its systemic healing effects—unlike BPC-157 which can be injected locally, TB-500 administered subcutaneously distributes broadly throughout the body. This makes it especially useful for athletes managing multiple simultaneous injuries or for systemic recovery support after major surgery.

Standard dosing: 2 to 5 mg twice weekly by subcutaneous injection during the acute healing phase (4 to 6 weeks), followed by 2 to 2.5 mg weekly for maintenance or gradual tapering.

TB-500 and BPC-157 are frequently stacked because their mechanisms are complementary and there are no known adverse interactions. The combination of local BPC-157 injection at the injury site plus systemic TB-500 twice weekly is a widely used protocol in sports medicine contexts. See the TB-500 guide for more detail.

GH Peptides for Post-Surgical Recovery

Growth hormone plays a central role in tissue repair—it upregulates protein synthesis, stimulates IGF-1 production (which drives cell proliferation), and improves nitrogen retention. The natural GH surge that occurs during deep sleep is one of the primary mechanisms driving nighttime tissue repair.

For major surgical recovery, GH secretagogues (CJC-1295/ipamorelin or sermorelin) can support accelerated healing by restoring more youthful GH pulsatility. Patients who are GH-deficient—a condition that becomes more common with age—are likely to benefit most. Evidence from the growth hormone literature in surgical patients shows improved wound tensile strength and faster recovery with GH optimization.

Practical consideration: GH peptides work over weeks to months, not days. For acute injury management, BPC-157 and TB-500 provide faster-onset healing support. GH peptides are most valuable as part of a longer-term recovery and rehabilitation strategy, particularly after major orthopedic surgery.

Pentadecapeptide (PDA): The Newer BPC Variant

Pentadecapeptide BPC (also sometimes referenced as PDA or "stable BPC") is a modified form of BPC-157 with improved stability under physiological conditions. Early research suggests comparable healing effects to BPC-157 with potentially better oral bioavailability—relevant for gut-healing applications and potentially for patients who prefer non-injectable administration.

For more information see our pentadecapeptide guide.

Bone Healing: PTH Analogs and GH Peptides

Bone injuries present a distinct healing biology from soft tissue. Fracture healing requires osteoblast activation, proper callus formation, and eventual remodeling—a process that can take months even in healthy young adults and is significantly impaired in older patients or those with osteoporosis.

BPC-157 has demonstrated bone healing acceleration in animal fracture models, including improved callus formation and tensile strength at the fracture site.

Teriparatide (PTH 1-34) is an FDA-approved synthetic parathyroid hormone analog primarily used for osteoporosis, but it has documented bone-healing effects when administered intermittently after fractures. It is one of the few bone-specific peptides with strong human clinical evidence. Coverage through insurance is possible for patients with established osteoporosis.

Growth hormone peptides support bone healing through IGF-1-mediated osteoblast stimulation. For patients recovering from stress fractures or facing orthopedic surgery, optimizing GH levels through CJC/ipamorelin creates a more anabolic systemic environment that supports both bone and soft tissue healing.

Copper Peptides for Wound Healing

GHK-Cu (glycine-histidine-lysine copper) is well established as a wound-healing peptide through decades of research, including documented effects in human studies. It promotes fibroblast proliferation, collagen and glycosaminoglycan synthesis, angiogenesis, and epithelial cell migration. Topically, GHK-Cu is used for skin wound healing and is one of the most evidence-supported peptides for this specific application. Systemically, it is used in some longevity and recovery protocols at 1 to 2 mg/day subcutaneously. See our GHK-Cu guide.

Intranasal Delivery for Brain and Nerve Injury

For traumatic brain injury (TBI) and peripheral nerve damage, intranasal delivery allows peptides to bypass the blood-brain barrier and act directly on neural tissue. BPC-157 has shown neuroprotective effects in TBI models. Semax, a nootropic neuropeptide, has evidence for stroke and TBI neuroprotection in Eastern European clinical literature.

For athletes who have experienced concussion or anyone managing TBI recovery, intranasal peptide administration warrants discussion with a provider experienced in both TBI management and peptide therapy. See our TBI peptides guide and intranasal peptides guide.

Designing a Recovery Protocol

Acute soft tissue injury (days 1–14):

• BPC-157 500 mcg subcutaneously near injury site daily
• TB-500 5 mg subcutaneously twice weekly
• Ice, compression, and offloading as appropriate; peptides do not replace rest

Subacute recovery (weeks 2–8):

• BPC-157 250–500 mcg daily, continuing
• TB-500 2.5 mg weekly
• Gradual progressive loading in physical therapy

Post-surgical recovery (weeks 1–12):

• Confirm timing with surgeon; most allow BPC-157 after incision closure (typically 1–2 weeks post-op)
• CJC-1295/ipamorelin added at weeks 2–4 for systemic anabolic and repair support
• Continue through physical therapy and functional restoration

Chronic injury (8+ weeks unresolved):

• Longer BPC-157 course: 12 to 20 weeks
• Consider intralesional injection if accessible site
• Address underlying contributing factors (biomechanics, nutrition, sleep, systemic inflammation)

For a broader view on what to expect during recovery protocols, see our peptide therapy results timeline.

Frequently Asked Questions

Q: How quickly does BPC-157 work for injury healing? Many patients report reduced pain and improved function within 1 to 2 weeks of starting BPC-157. Structural tissue healing (tendon, ligament) requires more time—typically 4 to 8 weeks for meaningful progress. Chronic injuries may require 12 to 16 weeks of consistent use.

Q: Can I use peptides immediately after surgery? Most surgeons recommend waiting until the surgical wound is closed and healing is underway before starting injectable peptides, typically 1 to 2 weeks post-operatively. Always consult your surgeon before adding any agent to a post-surgical recovery protocol.

Q: Is there human clinical trial evidence for BPC-157? BPC-157 has extensive animal model evidence but limited published human clinical trials. Anecdotal clinical use and case report data in humans is substantial, and it is widely used in sports medicine and regenerative medicine contexts. Formal RCT data in humans is currently limited but research is ongoing.

Q: Can peptides help heal old injuries that never fully resolved? Chronic injuries—particularly tendinopathies, ligament laxity, and old muscle tears—do respond to BPC-157 and TB-500 protocols, though typically requiring longer treatment courses (12 to 20 weeks) than acute injuries. The mechanism is the same: enhancing the biological signals for repair in tissue that has been in a chronic low-grade inflammatory or poorly vascularized state.

Q: Do I need a prescription for healing peptides? In the United States, BPC-157 and TB-500 occupy an ambiguous regulatory space. They are not FDA-approved drugs and are not controlled substances. They are available from compounding pharmacies with a prescription and from research chemical suppliers without one. Medical supervision is strongly recommended for post-surgical use and complex injury cases.